^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

PGR positive

i
Other names: PGR, Progesterone receptor, Nuclear receptor subfamily 3 group C member 3, NR3C3
Entrez ID:
Related biomarkers:
Phase 1
Mayo Clinic
Recruiting
Last update posted :
04/18/2024
Initiation :
09/23/2020
Primary completion :
08/15/2027
Completion :
08/15/2027
HER-2 • PD-L1 • ER • PGR • HMGB1
|
HER-2 positive • HER-2 negative • ER positive + PGR positive • PGR positive
Phase 3
SWOG Cancer Research Network
Active, not recruiting
Last update posted :
04/15/2024
Initiation :
11/01/2003
Primary completion :
01/01/2015
Completion :
01/01/2027
HER-2 • ER • PGR
|
ER positive • HER-2 amplification • ER negative • PGR positive • PGR negative
|
paclitaxel • doxorubicin hydrochloride • cyclophosphamide • Neulasta (pegfilgrastim)
Phase 1
Barbara Parker, MD
Completed
Last update posted :
04/10/2024
Initiation :
08/15/2018
Primary completion :
07/13/2021
Completion :
02/26/2024
HER-2 • ER • PGR
|
HER-2 negative • ER negative • ER positive + PGR positive • PGR positive • PGR negative
|
paclitaxel • zilovertamab (UC-961)
Phase N/A
Breast Cancer Trials, Australia and New Zealand
Recruiting
Last update posted :
04/09/2024
Initiation :
08/21/2017
Primary completion :
10/01/2025
Completion :
04/01/2026
HER-2 • PGR
|
HER-2 amplification • HER-2 negative • PGR positive
Phase N/A
University Hospital Augsburg
Recruiting
Last update posted :
04/08/2024
Initiation :
04/01/2024
Primary completion :
07/01/2024
Completion :
07/01/2027
HER-2 • ER • PGR
|
ER positive • ER positive + PGR positive • PGR positive • PGR negative
Phase N/A
Washington University School of Medicine
Recruiting
Last update posted :
04/08/2024
Initiation :
04/03/2024
Primary completion :
10/31/2031
Completion :
10/31/2031
HER-2 • PGR
|
HER-2 negative • ER positive + PGR positive • PGR positive
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
04/08/2024
Initiation :
05/04/2016
Primary completion :
04/04/2025
Completion :
04/04/2025
ER • PGR
|
ER negative • PGR positive • PGR negative
Phase 2
Novartis Pharmaceuticals
Active, not recruiting
Last update posted :
04/05/2024
Initiation :
06/11/2019
Primary completion :
06/11/2021
Completion :
07/01/2024
HER-2 • ER • PGR
|
ER positive • HER-2 negative • PGR positive
|
Kisqali (ribociclib) • letrozole • anastrozole • goserelin acetate
Phase 2
Merck Sharp & Dohme LLC
Recruiting
Last update posted :
04/05/2024
Initiation :
12/12/2018
Primary completion :
06/30/2026
Completion :
06/30/2026
BRCA1 • BRCA2 • HRD • BRCA
|
BRCA2 mutation • BRCA1 mutation • PGR positive • BRCA mutation
|
Lynparza (olaparib) • cisplatin
Phase N/A
SWOG Cancer Research Network
Recruiting
Last update posted :
04/04/2024
Initiation :
09/17/2018
Primary completion :
12/01/2030
Completion :
12/01/2036
HER-2 • ER • PGR
|
ER positive • HR positive • HER-2 negative • PGR positive
Phase 3
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
04/04/2024
Initiation :
01/18/2017
Primary completion :
05/31/2026
Completion :
05/31/2026
HER-2 • PD-L1 • ER • PGR • CD4
|
PD-L1 expression • HER-2 positive • ER positive • HER-2 negative • PGR positive
|
Keytruda (pembrolizumab) • Pembroria (pembrolizumab biosimilar)
Phase 3
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
04/04/2024
Initiation :
04/07/2006
Primary completion :
03/02/2018
Completion :
09/30/2030
HER-2
|
PGR positive
|
letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)
Phase 3
NRG Oncology
Recruiting
Last update posted :
04/02/2024
Initiation :
08/31/2023
Primary completion :
01/01/2032
Completion :
07/01/2034
HER-2 • PGR
|
HER-2 negative • PGR positive
|
triptorelin • goserelin acetate
Phase 3
NRG Oncology
Recruiting
Last update posted :
04/02/2024
Initiation :
06/07/2021
Primary completion :
01/01/2026
Completion :
07/01/2041
HER-2 • PGR
|
HER-2 negative • PGR positive
|
tamoxifen • letrozole • exemestane
Phase N/A
Washington University School of Medicine
Active, not recruiting
Last update posted :
03/21/2024
Initiation :
08/30/2018
Primary completion :
03/22/2026
Completion :
03/22/2026
PGR
|
ER positive + PGR positive • PGR positive
Phase 1
Dana-Farber Cancer Institute
Active, not recruiting
Last update posted :
03/18/2024
Initiation :
10/01/2018
Primary completion :
04/27/2022
Completion :
06/22/2025
BRCA1 • BRCA2 • BRCA
|
HER-2 positive • BRCA2 mutation • BRCA1 mutation • PGR positive
|
Lynparza (olaparib) • sapacitabine (CYC682)
Phase 1/2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
03/13/2024
Initiation :
06/17/2020
Primary completion :
06/22/2023
Completion :
03/11/2025
HER-2 • ER • PIK3CA • PGR • PTEN
|
HER-2 amplification • HER-2 negative • PGR positive
|
Verzenio (abemaciclib) • fulvestrant • Aliqopa (copanlisib)
Phase 2
Abramson Cancer Center at Penn Medicine
Recruiting
Last update posted :
03/12/2024
Initiation :
06/01/2021
Primary completion :
11/01/2024
Completion :
05/01/2028
HER-2 • ER • PGR
|
ER negative • PGR positive
|
Ibrance (palbociclib) • Bavencio (avelumab) • hydroxychloroquine
Phase 3
Novartis Pharmaceuticals
Completed
Last update posted :
03/12/2024
Initiation :
11/20/2014
Primary completion :
08/21/2017
Completion :
04/20/2023
HER-2 • ER • PGR
|
ER positive • HER-2 negative • PGR positive
|
tamoxifen • Kisqali (ribociclib) • letrozole • anastrozole • goserelin acetate
Phase 1
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
03/11/2024
Initiation :
05/02/2011
Primary completion :
11/25/2016
Completion :
03/07/2025
HER-2 • ER • PGR • BRCA1 • BRCA2 • BRCA
|
BRCA1 mutation • HER-2 negative • PGR positive • BRCA mutation • PARP1 expression
|
cyclophosphamide • veliparib (ABT-888)
Phase N/A
Washington University School of Medicine
Recruiting
Last update posted :
03/11/2024
Initiation :
08/12/2021
Primary completion :
06/30/2029
Completion :
06/30/2029
PGR
|
PGR positive
Phase 1
European Organisation for Research and Treatmen...
Completed
Last update posted :
03/08/2024
Initiation :
11/01/2006
Primary completion :
06/01/2009
Completion :
05/28/2010
ER • PGR
|
PGR positive
|
lapatinib • tamoxifen • Soltamox (tamoxifen citrate)
Phase N/A
Stanford University
Recruiting
Last update posted :
03/07/2024
Initiation :
03/22/2019
Primary completion :
09/01/2024
Completion :
07/01/2025
HER-2 • ER • PGR
|
HER-2 positive • ER positive • PGR positive
Phase 3
Fondazione Michelangelo
Completed
Last update posted :
03/07/2024
Initiation :
04/01/2013
Primary completion :
09/01/2016
Completion :
03/01/2023
HER-2 • ER • PGR
|
HER-2 negative • PGR positive
|
doxorubicin hydrochloride • albumin-bound paclitaxel • cyclophosphamide • epirubicin
Phase N/A
M.D. Anderson Cancer Center
Recruiting
Last update posted :
03/07/2024
Initiation :
01/20/2017
Primary completion :
01/31/2026
Completion :
01/31/2026
ER • PGR
|
HER-2 positive • HER-2 negative • PGR positive
Phase 2
National Cancer Centre, Singapore
Recruiting
Last update posted :
03/05/2024
Initiation :
02/15/2023
Primary completion :
12/31/2025
Completion :
12/31/2026
HER-2 • ER • PGR
|
ER positive • HER-2 amplification • HER-2 negative • PGR positive
|
Keytruda (pembrolizumab) • Lenvima (lenvatinib) • letrozole
Phase 3
West German Study Group
Recruiting
Last update posted :
03/01/2024
Initiation :
09/02/2020
Primary completion :
08/01/2026
Completion :
03/01/2028
HER-2 • ER • PGR
|
ER positive • HER-2 negative • PGR positive
|
tamoxifen • Verzenio (abemaciclib)
Phase 2
University of Michigan Rogel Cancer Center
Completed
Last update posted :
02/29/2024
Initiation :
07/28/2020
Primary completion :
02/27/2024
Completion :
02/27/2024
ER • PGR
|
ER positive • PGR positive
Phase 2
Novartis Pharmaceuticals
Active, not recruiting
Last update posted :
02/28/2024
Initiation :
08/29/2018
Primary completion :
04/25/2022
Completion :
12/11/2024
HER-2 • ER • PGR
|
ER positive • HER-2 negative • PGR positive
|
Kisqali (ribociclib) • letrozole • anastrozole • goserelin acetate
Phase 3
Henan Cancer Hospital
Recruiting
Last update posted :
02/26/2024
Initiation :
09/28/2021
Primary completion :
09/01/2024
Completion :
09/01/2028
HER-2 • ER • PGR
|
HER-2 negative • PGR positive
|
capecitabine
Phase 3
Novartis Pharmaceuticals
Completed
Last update posted :
02/23/2024
Initiation :
02/02/2018
Primary completion :
12/11/2023
Completion :
12/11/2023
HER-2 • ER • PIK3CA • PGR • PTEN • CDKN2A • CCND1
|
ER positive • HER-2 negative • PIK3CA mutation • PGR positive
|
Piqray (alpelisib) • Kisqali (ribociclib) • fulvestrant • letrozole
Phase 2
German Breast Group
Recruiting
Last update posted :
02/22/2024
Initiation :
01/02/2023
Primary completion :
10/01/2026
Completion :
01/01/2027
HER-2 • PIK3CA • PGR
|
HER-2 positive • PIK3CA mutation • ER positive + PGR positive • PGR positive • PGR positive + HER-2 positive
|
Herceptin (trastuzumab) • tamoxifen • Perjeta (pertuzumab) • inavolisib (GDC-0077) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
Phase 3
Novartis Pharmaceuticals
Recruiting
Last update posted :
02/22/2024
Initiation :
04/10/2024
Primary completion :
09/07/2029
Completion :
09/20/2030
HER-2 • ER • PGR
|
ER positive • HER-2 negative • PGR positive
|
Kisqali (ribociclib) • letrozole • exemestane • goserelin acetate • leuprolide acetate for depot suspension
Phase 2
Beth Israel Deaconess Medical Center
Active, not recruiting
Last update posted :
02/19/2024
Initiation :
04/01/2018
Primary completion :
07/30/2024
Completion :
12/30/2024
PGR • BRCA1 • BRCA2 • BRCA • CHEK2 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC
|
BRCA2 mutation • BRCA1 mutation • HR positive • PALB2 mutation • PGR positive • BRCA mutation
|
Lynparza (olaparib)
Phase 2
City of Hope Medical Center
Completed
Last update posted :
02/19/2024
Initiation :
06/14/2018
Primary completion :
09/29/2021
Completion :
06/05/2023
HER-2 • ER • PGR
|
ER positive • HER-2 negative • PGR positive
|
Kisqali (ribociclib)
Phase N/A
Medical College of Wisconsin
Not yet recruiting
Last update posted :
02/19/2024
Initiation :
03/15/2024
Primary completion :
07/15/2027
Completion :
07/15/2027
HER-2 • ER • PGR
|
ER positive • HER-2 negative • PGR positive
Phase N/A
University of Wisconsin, Madison
Recruiting
Last update posted :
02/15/2024
Initiation :
11/16/2022
Primary completion :
11/01/2025
Completion :
11/01/2025
HER-2 • ER • PGR
|
PGR positive
Phase N/A
IceCure Medical Ltd.
Active, not recruiting
Last update posted :
02/14/2024
Initiation :
10/01/2014
Primary completion :
03/01/2024
Completion :
06/01/2024
HER-2 • ER • PGR
|
ER positive • HER-2 negative • PGR positive
Phase 1/2
Centre Leon Berard
Active, not recruiting
Last update posted :
02/13/2024
Initiation :
04/01/2016
Primary completion :
11/01/2019
Completion :
12/01/2024
ER • PGR • ABCB1
|
PGR positive
|
anastrozole • vistusertib (AZD2014)